RetinalGenix Technologies (RTGN) Cash & Equivalents Growth (1y) (2021 - 2026)
RetinalGenix Technologies (RTGN) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.70 Bn | 194.10 Bn | 7.27 Bn | -26.57% |
| 2 | Stryker | 127.86 Bn | 124.38 Bn | 4.50 Bn | 42.78% |
| 3 | Medtronic | 119.05 Bn | 109.83 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 73.61 Bn | 73.07 Bn | 3.85 Bn | 0.94% |
| 5 | Edwards Lifesciences | 52.00 Bn | 47.75 Bn | 1.35 Bn | -11.19% |
| 6 | Dexcom | 34.36 Bn | 32.42 Bn | 830.00 Mn | -4.66% |
| 7 | GE HealthCare Technologies | 33.85 Bn | 31.74 Bn | 2.18 Bn | -44.03% |
| 8 | Koninklijke Philips | 26.38 Bn | 23.06 Bn | 4.55 Bn | 19.49% |
| 9 | Steris | 23.08 Bn | 22.59 Bn | 684.20 Mn | 72.43% |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | -95.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.15% |
| Dec 31, 2025 | 143.80% |
| Sep 30, 2025 | -99.88% |
| Jun 30, 2025 | -99.03% |
| Mar 31, 2025 | -92.63% |
| Sep 30, 2024 | 179,647.73% |
| Jun 30, 2024 | 4,443.28% |
| Mar 31, 2024 | 574.51% |
| Sep 30, 2023 | -98.79% |
| Jun 30, 2023 | 6,985.19% |
| Mar 31, 2023 | 192.37% |
| Dec 31, 2022 | -99.23% |
| Sep 30, 2022 | -90.07% |
| Dec 31, 2021 | 122.94% |